BridgeBio Oncology Therapeutics, Inc (BBOT) vs Evommune Inc. (EVMN)

BridgeBio Oncology Therapeutics, Inc and Evommune Inc. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Evommune Inc. are of similar size ($319.9M and $309.9M). Across the 10 metrics below, Evommune Inc. leads on 6 and BridgeBio Oncology Therapeutics, Inc on 4.

Valuation

Metric BBOT EVMN Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 0.98 1.10 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield (69.87%) (130.22%) (28.84%)
Free cash flow yield (47.93%) (24.39%) (23.03%)

Profitability

Metric BBOT EVMN Biotechnology median
Gross margin — — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (252.10%) (141.99%) (57.72%)
Return on assets (96.69%) (62.71%) (49.22%)
Return on invested capital (127.66%) (82.46%) 0.00%

Growth

Metric BBOT EVMN Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 99.93% 75.23% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric BBOT EVMN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 11.68 4.73
Net debt to EBITDA 2.93 1.87 0.96

Dividend

Metric BBOT EVMN Biotechnology median
Dividend yield — — 2.10%
Payout ratio — — 0.00

Size

Metric BBOT EVMN Biotechnology median
Market cap 319.90m 309.93m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack